"While the response observed in our squamous cell carcinoma of the skin study with tarloxotinib was encouraging, the overall results from the two studies didn't meet the activity thresholds required to move forward the molecule forward despite the promising results seen in preclinical translational studies,β said Barry Selick, Ph.D., Chief Executive Officer of Threshold. "As a result, we are making no further investment in this program.
βThe efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!β
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.